Business Trip Frontier investable areas in brain health with PsyMed Ventures
22 snips
Feb 25, 2025 Brooks Leitner, MD/PhD, newest partner at PsyMed Ventures and expert in neuroscience from Yale and the NIH, discusses the future of brain health investments. He emphasizes a human-first approach, shifting from animal models to clinical insights. The conversation covers emerging investment areas like therapeutics, diagnostics, and AI-enabled care. Brooks also shares his thoughts on leadership challenges, innovative strategies in personal health, and the evolving landscape of mental health innovations that can reshape therapies and enhance patient care.
AI Snips
Chapters
Transcript
Episode notes
Expanding the Scope
- Psychedelics' potential to address the mental health crisis sparked initial interest in the field.
- The problem's scope and the range of solutions proved much broader than just psychedelics.
Mental Health's Broad Impact
- Mental health's impact extends beyond traditional diagnoses like depression and anxiety.
- It affects various areas such as obesity, dementia, and even autoimmune diseases.
Brain's Resistance to Traditional Approaches
- The brain's complexity makes it difficult to reduce behavioral diagnoses to single genes or proteins.
- Defining brain health and disease requires a different perspective than other medical fields.